Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

BIOLOGICAL2 trials

Sponsors

Sinovac Life Sciences Co., Ltd., Sinovac Research and Development Co., Ltd.

Conditions

COVID-19

Phase 1

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

CompletedNCT04383574

Sinovac Life Sciences Co., Ltd.COVID-19

Start: 2020-05-22End: 2022-05-31Updated: 2022-08-11

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

CompletedNCT04551547

Sinovac Research and Development Co., Ltd.COVID-19

Start: 2020-10-31End: 2023-02-08Updated: 2023-10-02

Related Papers

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents

Nature Communications2022-11-1411 citations

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.

2022-06-0319 citations

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.

2021-12-08234 citations

Coronavirus disease 2019 vaccine for children in China: when to start? Mandatory or voluntary?

Chinese Medical Journal2021-09-214 citations

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.

2021-06-28242 citations

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

2021-02-03393 citations

Understanding COVID-19 Vaccines and Their Development

Journal of Bone and Joint Surgery2020-07-316 citations